Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26998424
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Bone+Oncol
2016 ; 5
(1
): 30-7
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
P62: An emerging oncotarget for osteolytic metastasis
#MMPMID26998424
Zhang J
; Yang Z
; Dong J
J Bone Oncol
2016[Mar]; 5
(1
): 30-7
PMID26998424
show ga
Bone metastasis occurs in the majority of late-stage tumors with poor prognosis.
It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The
pathogenesis of osteolytic metastasis is a "vicious cycle" between tumor cells
and bone cells (primarily the osteoclasts), which is mediated by secretory
factors. The P62 adapter protein is a versatile multitasker between tumor cells
and bone cells. The overexpression of P62 has been detected among a variety of
tumors, playing positive roles in both tumorigenesis and metastasis. Moreover,
P62 is an important modulator of the osteoclastogenesis pathway. Therefore, the
ability of P62 to modulate tumors and osteoclasts suggests that it may be a
feasible oncotarget for bone metastasis, especially for osteolytic metastasis.
Recent research has shown that a P62 DNA vaccine triggered effective anti-tumor,
anti-metastatic and anti-osteoporotic activities. Growing lines of evidence point
to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we
outline the different roles of P62 in tumor cells and osteoclasts, focusing on
the P62-related signaling pathway in key steps of osteolytic metastasis,
including tumorigenesis, metastasis and osteoclastogenesis. Finally, we discuss
the newest observations on P62 as an oncotarget for osteolytic metastasis
treatment.
free
free
free
